Two drugs, dexamethasone and pomalidomide, in combination with belantamab mafodotin or bortezomib, to treat multiple myeloma that has come back (relapsed) or has not gotten better with treatment (refractory)

To find out if the combination of belantamab mafodotin, dexamethasone and pomalidomide is safe and works better to treat multiple myeloma that has relapsed or is refractory compared to bortezomib, dexamethasone and pomalidomide

Belantamab mafodotin is an antibody-drug conjugate, or combination, that targets BCMA on certain cells. 
Bortezomib is a small molecule inhibitor that blocks proteasome function in certain cells. Pomalidomide is a drug that blocks the growth of cancer cells.  

In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in: 

Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.  

You’ll get:

You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 7 years.    

The Food and Drug Administration (FDA) has approved all of the drugs used in this trial to treat multiple myeloma. Using them together in this way to treat multiple myeloma that has relapsed or is refractory is new and unproven.